Chlamydia pneumoniae and coronary artery disease: the antibiotic trials.
Parallel with the mounting evidence that atherosclerosis has a major inflammatory component, provoking agents that may initiate and drive this process have been sought. Infectious agents such as Chlamydia pneumoniae have been alleged to be activators of inflammation that may contribute to atherosclerosis and thus coronary artery disease (CAD) and its associated complications. A logical pneumoniae extension of this theory whether treating C pneumoniae infection with antibiotics and/or modulating inflammatory processes can affect CAD and its sequelae. This article discusses the potential role of C pneumoniae in atherosclerosis, its detection, and the rationale for antibiotics. Additionally, it summarizes the current randomized clinical trials of antichlamydial antibiotics in patients with CAD and draws conclusions based on the results.
Higgins
John P
JP
Department of Medicine, University of Oklahoma, Tulsa, USA. jphboston@hotmail.com
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D023521:Chlamydophila Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D016993:Chlamydophila pneumoniae; D003324:Coronary Artery Disease / Q000150:complications* / Q000382:microbiology; D006801:Humans; D016032:Randomized Controlled Trials as Topic
D000900:Anti-Bacterial Agents